BR112018074532A2 - composição farmacêutica, aerossol, e, kit. - Google Patents
composição farmacêutica, aerossol, e, kit.Info
- Publication number
- BR112018074532A2 BR112018074532A2 BR112018074532-4A BR112018074532A BR112018074532A2 BR 112018074532 A2 BR112018074532 A2 BR 112018074532A2 BR 112018074532 A BR112018074532 A BR 112018074532A BR 112018074532 A2 BR112018074532 A2 BR 112018074532A2
- Authority
- BR
- Brazil
- Prior art keywords
- pro
- neutrophil elastase
- pharmaceutical
- octg
- dpro
- Prior art date
Links
- 239000008249 pharmaceutical aerosol Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 2
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000052502 human ELANE Human genes 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- BATWGBRIZANGPN-ZPFDUUQYSA-N Ile-Pro-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BATWGBRIZANGPN-ZPFDUUQYSA-N 0.000 abstract 1
- 108010028275 Leukocyte Elastase Proteins 0.000 abstract 1
- 102000016799 Leukocyte elastase Human genes 0.000 abstract 1
- LANQLYHLMYDWJP-SRVKXCTJSA-N Pro-Gln-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O LANQLYHLMYDWJP-SRVKXCTJSA-N 0.000 abstract 1
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
a presente invenção refere-se a aerossóis farmacêuticos compreendendo uma folha beta peptidomimética de fórmula ciclo( octg glu thr ala ser ile pro pro gln lys tyr dpro pro ), ou um sal farmaceuticamente aceitável do mesmo, tendo atividade inibitória contra a elastase neutrofílica de humanos. refere-se ainda a composições farmacêuticas sólidas ou líquidas e kits para preparar e administrar tais aerossóis. a invenção pode ser usada para prevenção, controle ou tratamento de doenças pulmonares, tais como, deficiência de alfa-1 antitripsina (daat), fibrose cística (fc), bronquiectasia não fibrose cística (bfnc) ou doença pulmonar obstrutiva crônica (dpoc), ou infecções, ou doenças, ou condições dos pulmões, sendo mediadas pela ou resultantes da atividade de elastase neutrofílica de humanos. assim, a invenção refere-se ainda a uma composição farmacêutica ou um aerossol farmacêutico compreendendo o composto ativo ciclo( octg glu thr ala ser ile pro pro gln lys tyr dpro pro ), ou qualquer sal farmaceuticamente aceitável do mesmo, para uso em um método para prevenção, controle ou tratamento de doenças ou condições dos pulmões sendo mediadas pela ou resultantes da atividade de elastase neutrofílica de humanos em um indivíduo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020210.7 | 2016-05-31 | ||
| EP16020210 | 2016-05-31 | ||
| PCT/EP2017/025157 WO2017207118A1 (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018074532A2 true BR112018074532A2 (pt) | 2019-03-19 |
| BR112018074532B1 BR112018074532B1 (pt) | 2022-02-08 |
Family
ID=56108445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018074532-4A BR112018074532B1 (pt) | 2016-05-31 | 2017-05-31 | Composição farmacêutica, aerossol, e, kit. |
| BR112018074551-0A BR112018074551B1 (pt) | 2016-05-31 | 2017-05-31 | Aerossol farmacêutico, composições farmacêuticas líquida e sólida, kit, e, método para preparar e dispensar um aerossol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018074551-0A BR112018074551B1 (pt) | 2016-05-31 | 2017-05-31 | Aerossol farmacêutico, composições farmacêuticas líquida e sólida, kit, e, método para preparar e dispensar um aerossol |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11235024B2 (pt) |
| EP (2) | EP3463281B1 (pt) |
| JP (4) | JP7286319B6 (pt) |
| KR (2) | KR102511284B1 (pt) |
| CN (3) | CN109310613A (pt) |
| AU (2) | AU2017273507B2 (pt) |
| BR (2) | BR112018074532B1 (pt) |
| CA (2) | CA3024521C (pt) |
| CL (2) | CL2018003391A1 (pt) |
| DK (2) | DK3463280T3 (pt) |
| EA (2) | EA201892819A1 (pt) |
| ES (2) | ES2927948T3 (pt) |
| HR (2) | HRP20221185T1 (pt) |
| HU (2) | HUE060393T2 (pt) |
| IL (2) | IL263112B2 (pt) |
| LT (2) | LT3463280T (pt) |
| MA (2) | MA45168A (pt) |
| MX (2) | MX2018014752A (pt) |
| PH (2) | PH12018502521A1 (pt) |
| PL (2) | PL3463280T3 (pt) |
| PT (2) | PT3463281T (pt) |
| RS (2) | RS63622B1 (pt) |
| SG (3) | SG11201810137UA (pt) |
| UA (2) | UA125900C2 (pt) |
| WO (2) | WO2017207118A1 (pt) |
| ZA (2) | ZA201807772B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3463280T (lt) * | 2016-05-31 | 2022-09-26 | Spexis Ag | Beta plaukų segtuko struktūros peptido mimetikas, pasižymintis elastazės slopiklio aktyvumu ir jo aerozolinės vaisto formos |
| WO2021041264A1 (en) * | 2019-08-23 | 2021-03-04 | Ph Pharma Co., Ltd. | Use of a neutrophil elastase inhibitor in lung disease |
| CA3168807A1 (en) * | 2020-01-30 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Methods of treatment for alpha-1 antitrypsin deficiency |
| IL303021A (en) * | 2020-11-23 | 2023-07-01 | Spexis Ag | Peptidomimetic beta-herpain compositions and spray dosage forms thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE229812T1 (de) * | 1996-11-01 | 2003-01-15 | Xoma Technology Ltd | Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose |
| AU2006206272A1 (en) | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
| WO2006087001A1 (en) * | 2005-02-17 | 2006-08-24 | Polyphor Ltd. | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| BRPI0707634A2 (pt) * | 2006-02-09 | 2011-05-10 | Kamada Ltd | alfa-1 antitripsina para tratar episàdios de exacerbaÇço de doenÇas pulmonares |
| LT1991201T (lt) * | 2006-02-10 | 2018-07-25 | Pari Pharma Gmbh | Puškiami antibiotikai inhaliaciniam gydymui |
| WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
| PL2567691T3 (pl) * | 2011-09-12 | 2015-05-29 | Meiji Seika Pharma Co Ltd | Kompozycje wodne obejmujące arbekacynę |
| WO2015096672A1 (zh) | 2013-12-23 | 2015-07-02 | 石家庄铁道大学 | 测试装置 |
| WO2015098872A1 (ja) | 2013-12-26 | 2015-07-02 | 株式会社カネカ | 太陽電池のｉ‐ｖ測定方法、太陽電池のｉ‐ｖ測定装置、太陽電池の製造方法、太陽電池モジュールの製造方法、および太陽電池モジュール |
| WO2015096873A1 (en) * | 2013-12-27 | 2015-07-02 | Polyphor Ag | Beta-hairpin peptidomimetics as selective elastase inhibitors |
| MX2016008468A (es) * | 2013-12-27 | 2016-09-26 | Polyphor Ag | Peptidomimeticos de horquilla beta como inhibidores de elastasa selectivos. |
| LT3463280T (lt) * | 2016-05-31 | 2022-09-26 | Spexis Ag | Beta plaukų segtuko struktūros peptido mimetikas, pasižymintis elastazės slopiklio aktyvumu ir jo aerozolinės vaisto formos |
-
2017
- 2017-05-31 LT LTEPPCT/EP2017/025156T patent/LT3463280T/lt unknown
- 2017-05-31 WO PCT/EP2017/025157 patent/WO2017207118A1/en unknown
- 2017-05-31 SG SG11201810137UA patent/SG11201810137UA/en unknown
- 2017-05-31 SG SG10202113280XA patent/SG10202113280XA/en unknown
- 2017-05-31 AU AU2017273507A patent/AU2017273507B2/en active Active
- 2017-05-31 WO PCT/EP2017/025156 patent/WO2017207117A1/en unknown
- 2017-05-31 ES ES17733737T patent/ES2927948T3/es active Active
- 2017-05-31 PT PT177337383T patent/PT3463281T/pt unknown
- 2017-05-31 UA UAA201812930A patent/UA125900C2/uk unknown
- 2017-05-31 MA MA045168A patent/MA45168A/fr unknown
- 2017-05-31 BR BR112018074532-4A patent/BR112018074532B1/pt active IP Right Grant
- 2017-05-31 CA CA3024521A patent/CA3024521C/en active Active
- 2017-05-31 US US16/305,714 patent/US11235024B2/en active Active
- 2017-05-31 DK DK17733737.5T patent/DK3463280T3/da active
- 2017-05-31 PL PL17733737.5T patent/PL3463280T3/pl unknown
- 2017-05-31 HU HUE17733738A patent/HUE060393T2/hu unknown
- 2017-05-31 JP JP2018562561A patent/JP7286319B6/ja active Active
- 2017-05-31 EP EP17733738.3A patent/EP3463281B1/en active Active
- 2017-05-31 MX MX2018014752A patent/MX2018014752A/es unknown
- 2017-05-31 LT LTEPPCT/EP2017/025157T patent/LT3463281T/lt unknown
- 2017-05-31 KR KR1020187036055A patent/KR102511284B1/ko active IP Right Grant
- 2017-05-31 RS RS20220923A patent/RS63622B1/sr unknown
- 2017-05-31 IL IL263112A patent/IL263112B2/en unknown
- 2017-05-31 HR HRP20221185TT patent/HRP20221185T1/hr unknown
- 2017-05-31 AU AU2017273508A patent/AU2017273508B2/en active Active
- 2017-05-31 IL IL263114A patent/IL263114B2/en unknown
- 2017-05-31 EA EA201892819A patent/EA201892819A1/ru unknown
- 2017-05-31 EP EP17733737.5A patent/EP3463280B1/en active Active
- 2017-05-31 RS RS20220922A patent/RS63639B1/sr unknown
- 2017-05-31 KR KR1020187036054A patent/KR102480800B1/ko active IP Right Grant
- 2017-05-31 US US16/305,518 patent/US11235023B2/en active Active
- 2017-05-31 DK DK17733738.3T patent/DK3463281T3/da active
- 2017-05-31 CA CA3024522A patent/CA3024522C/en active Active
- 2017-05-31 MX MX2018014425A patent/MX2018014425A/es unknown
- 2017-05-31 BR BR112018074551-0A patent/BR112018074551B1/pt active IP Right Grant
- 2017-05-31 CN CN201780033188.1A patent/CN109310613A/zh active Pending
- 2017-05-31 PL PL17733738.3T patent/PL3463281T3/pl unknown
- 2017-05-31 MA MA045167A patent/MA45167A/fr unknown
- 2017-05-31 HR HRP20221194TT patent/HRP20221194T1/hr unknown
- 2017-05-31 SG SG11201810138XA patent/SG11201810138XA/en unknown
- 2017-05-31 PT PT177337375T patent/PT3463280T/pt unknown
- 2017-05-31 JP JP2018562549A patent/JP2019523222A/ja active Pending
- 2017-05-31 EA EA201892818A patent/EA039603B1/ru unknown
- 2017-05-31 ES ES17733738T patent/ES2928050T3/es active Active
- 2017-05-31 CN CN201780033187.7A patent/CN109195580A/zh active Pending
- 2017-05-31 CN CN202211636345.7A patent/CN116159024A/zh active Pending
- 2017-05-31 HU HUE17733737A patent/HUE060119T2/hu unknown
- 2017-05-31 UA UAA201812929A patent/UA125899C2/uk unknown
-
2018
- 2018-11-19 ZA ZA2018/07772A patent/ZA201807772B/en unknown
- 2018-11-19 ZA ZA2018/07773A patent/ZA201807773B/en unknown
- 2018-11-28 CL CL2018003391A patent/CL2018003391A1/es unknown
- 2018-11-28 CL CL2018003390A patent/CL2018003390A1/es unknown
- 2018-11-29 PH PH12018502521A patent/PH12018502521A1/en unknown
- 2018-11-29 PH PH12018502522A patent/PH12018502522A1/en unknown
-
2021
- 2021-10-06 US US17/495,137 patent/US11844823B2/en active Active
-
2022
- 2022-01-04 JP JP2022000083A patent/JP2022078013A/ja active Pending
- 2022-10-20 JP JP2022168582A patent/JP2023017793A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ryter et al. | Autophagy in lung disease pathogenesis and therapeutics | |
| BR112018074532A2 (pt) | composição farmacêutica, aerossol, e, kit. | |
| dos Santos et al. | The inflammasome in lung diseases | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
| NO20082791L (no) | 6-fenyl-1H-imidazo[4,5-C]-pyridin-4-karbonitrilderivater som Cathepsin K- og S-inhibitorer | |
| WO2014008248A3 (en) | Compositions and methods for treating and inhibiting viral infections | |
| BR112018012022A2 (pt) | ?composição, e, método para tratamento ou redução do risco de colestase intra-hepática? | |
| JP2023123440A (ja) | 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| JP2016196419A (ja) | 皮膚外用製剤 | |
| BR112014032244A2 (pt) | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica | |
| JP2008088189A5 (pt) | ||
| BR112019018028A2 (pt) | Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| EA202090763A1 (ru) | Фармацевтическая композиция для стимуляции деления стволовых клеток и подавления вирулентности бактерий | |
| CO2020009992A2 (es) | Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación | |
| Duan et al. | Diphenyl pyrimidine exhibits protective effect on Staphylococcus aureus pneumonia in rat model by targeting NLRP3 expression | |
| BRPI0720251B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo | |
| WO2017091167A1 (en) | Topical pharmaceutical composition comprising fusidic acid, isoconazole, dexpanthenol and hydrocortisone | |
| JP6294773B2 (ja) | 口腔粘膜疾患の予防または治療用経口製剤 | |
| Haynes et al. | Neutrophil Infiltration and Function in the Pathogenesis of Inflammatory Airspace Disease | |
| Diamant et al. | Effect of multiple-dose setipiprant, a selective oral CRTH2 antagonist, on allergen-induced airway responses in allergic asthmatic patients | |
| JPWO2016035804A1 (ja) | 掻痒性皮膚疾患の治療又は予防剤 | |
| JP5227016B2 (ja) | 痒み抑制剤および痒み抑制組成物 | |
| KASHYAP | Influence of topical retapamulin (1%) ointment, sofinox-rd cream, sofinox cream (2%), zinc fusidate cream (2%) and zinc fusidate ointment (2%) on nasal mucosal surface safety in new zealand albino rabbits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/05/2017, OBSERVADAS AS CONDICOES LEGAIS. |